このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effect of Hydrogen-rich Water During Tapering on Recovery After Functional Overreaching in Basketball Players

2026年7月27日 更新者:Jakub Krejci、Palacky University

Effect of Hydrogen-rich Water Supplementation During Tapering on Recovery After Functional Overreaching in Competitive Male Basketball Players: A Randomized, Double-blind, Placebo-controlled Paralel-group Trial

The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:

  • Does hydrogen-rich water improve autonomic recovery after functional overreaching?
  • Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering?

Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:

  • Complete a training cycle including normal training, functional overreaching, and tapering.
  • Consume hydrogen-rich or placebo water daily during the one-week tapering period.
  • Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.

調査の概要

詳細な説明

The study consists of an initial screening and entry testing phase, followed by one week of normal training, two weeks of functional overreaching, and one week of tapering. During the functional overreaching period, training load is increased to approximately 120-130% of normal training load to induce accumulated fatigue. During the tapering period, training volume is reduced to approximately 50-60% of normal training volume to support recovery and performance rebound.

The molecular hydrogen is administered only during the tapering period. Participants in the experimental group consume 2.5 L per day of hydrogen-rich water. The total daily dose is divided into 0.5 L in the morning, 1.5 L around training, and 0.5 L in the evening. Participants in the placebo group consume visually matched placebo water according to the same total daily intake and timing schedule. Supplementation adherence is monitored using logs, dose counts, and attendance records. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the placebo group. Randomization is performed using a block scheme and a computer random number generator.

Testing is performed at multiple time points: entry laboratory testing, baseline after normal training, post-functional overreaching, and post-taper. The primary interval for evaluation is the change from post-functional overreaching to post-taper. Statistical analysis is based on a t-test or analysis of variance. Data that not follow a normal distribution are treated using a logarithmic transformation or analyzed using nonparametric tests. The significance level is set at 0.05.

研究の種類

介入

入学 (推定)

30

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Olomouc、チェコ、77111
        • 募集
        • Palacky University, Faculty of Physical Culture
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Competitive male basketball players.
  • Signed informed consent.
  • Completion of entry medical and laboratory screening.

Exclusion Criteria:

  • Acute injury or infection.
  • History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
  • Use of medication affecting recovery markers or study results.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Hydrogen-rich water
Hydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period.
Hydrogen-rich water with molecular hydrogen concentration >1.0 ppm.
他の名前:
  • Tirtan generator (Nutristamina, Ostrava, Czech Republic)
プラセボコンパレーター:Placebo water
Placebo water administered at a dose of 2.5 L per day during a one-week tapering period.
Tap water without molecular hydrogen.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
RMSSD
時間枠:One-week change between post-overreaching and post-taper.
The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.
One-week change between post-overreaching and post-taper.

二次結果の測定

結果測定
メジャーの説明
時間枠
Creatine kinase
時間枠:One-week change between post-overreaching and post-taper.
Blood creatine kinase concentration is used as a marker of muscle damage.
One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein
時間枠:One-week change between post-overreaching and post-taper.
High-sensitivity C-reactive protein concentration is used as a marker of systemic inflammatory.
One-week change between post-overreaching and post-taper.
Cortisol
時間枠:One-week change between post-overreaching and post-taper.
Blood cortisol concentration is used as a marker of physiological stress response.
One-week change between post-overreaching and post-taper.
Testosterone
時間枠:One-week change between post-overreaching and post-taper.
Blood testosterone concentration is used as a marker related to anabolic-catabolic balance.
One-week change between post-overreaching and post-taper.
Urea
時間枠:One-week change between post-overreaching and post-taper.
Blood urea concentration is used as a marker related to metabolic and protein-turnover stress.
One-week change between post-overreaching and post-taper.
Leukocytes
時間枠:One-week change between post-overreaching and post-taper.
Blood leukocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Lymphocytes
時間枠:One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of immune-related response to training.
One-week change between post-overreaching and post-taper.
Neutrophils
時間枠:One-week change between post-overreaching and post-taper.
Blood lymphocyte count is used as a marker of imflammatory response to training.
One-week change between post-overreaching and post-taper.
Reactive strength index
時間枠:One-week change between post-overreaching and post-taper.
Reactive strength index is used as an marker of neuromuscular function of the lower limbs and is measured using a drop jump.
One-week change between post-overreaching and post-taper.
Hangrip test
時間枠:One-week change between post-overreaching and post-taper.
Handgrip test is used as a marker of forearm muscle strength and is measured using a dynamometer.
One-week change between post-overreaching and post-taper.
20-m sprint
時間枠:One-week change between post-overreaching and post-taper.
20-m sprint test is used to assess linear speed.
One-week change between post-overreaching and post-taper.
Repeated sprint
時間枠:One-week change between post-overreaching and post-taper.
20 x 15 m repeated sprint test is used to asses repeated sprint ability.
One-week change between post-overreaching and post-taper.
Agility T-test
時間枠:One-week change between post-overreaching and post-taper.
Agility T-test is used to assess planned change-of-direction performance.
One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test
時間枠:One-week change between post-overreaching and post-taper.
Basketball jump shot accuracy test is used to assess basketball-specific performance.
One-week change between post-overreaching and post-taper.
Muscle soreness
時間枠:One-week change between post-overreaching and post-taper.
Muscle soreness is assessed subjectively using a visual analog scale, which is represented by a 100 mm line marked 0 (no pain) and 100 (worst imaginable pain).
One-week change between post-overreaching and post-taper.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jan Kvas、Palacky University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年7月27日

一次修了 (推定)

2026年12月1日

研究の完了 (推定)

2026年12月1日

試験登録日

最初に提出

2026年7月15日

QC基準を満たした最初の提出物

2026年7月15日

最初の投稿 (実際)

2026年7月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月28日

QC基準を満たした最後の更新が送信されました

2026年7月27日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • FTK_2026_13

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All IPD that underlie results in a publication.

IPD 共有時間枠

Beginning 1 month after the publication of results with no end date.

IPD 共有アクセス基準

Anonymized IPD will be uploaded to an open-access data repository.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する